secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-311276
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx: anito-cel achieves 96% ORR, 74% CR/sCR in pivotal RRMM study
---------------------------------------------------------------------

- 96% ORR (112/117) and 74% CR/sCR (86/117); 95% MRD negativity (91/96) at 10^-5 sensitivity.
- 12-month PFS 82.1%, OS 94.0%; 24-month PFS 61.7%, OS 83.0% in 4L+ triple/penta-refractory patients.
- No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) observed; all patients dosed >12 months.
- Company reiterates planned 2026 commercial launch; building commercial and medical affairs organization.
- Data presented at ASH; BLA submission underway with Oct 2025 data cutoff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525311276/0001193125-25-311276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525311276/d89813d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer